Anti-NAB1 monoclonal antibody

Pre-made anti-NAB1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to NAB1/NAB1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2621-Ab-1/ GM-Tg-hg-IP2621-Ab-2Anti-Human NAB1 monoclonal antibodyHuman
GM-Tg-rg-IP2621-Ab-1/ GM-Tg-rg-IP2621-Ab-2Anti-Rat NAB1 monoclonal antibodyRat
GM-Tg-mg-IP2621-Ab-1/ GM-Tg-mg-IP2621-Ab-2Anti-Mouse NAB1 monoclonal antibodyMouse
GM-Tg-cynog-IP2621-Ab-1/ GM-Tg-cynog-IP2621-Ab-2Anti-Cynomolgus/ Rhesus macaque NAB1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2621-Ab-1/ GM-Tg-felg-IP2621-Ab-2Anti-Feline NAB1 monoclonal antibodyFeline
GM-Tg-cang-IP2621-Ab-1/ GM-Tg-cang-IP2621-Ab-2Anti-Canine NAB1 monoclonal antibodyCanine
GM-Tg-bovg-IP2621-Ab-1/ GM-Tg-bovg-IP2621-Ab-2Anti-Bovine NAB1 monoclonal antibodyBovine
GM-Tg-equg-IP2621-Ab-1/ GM-Tg-equg-IP2621-Ab-2Anti-Equine NAB1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2621-Ab-1/ GM-Tg-hg-IP2621-Ab-2; GM-Tg-rg-IP2621-Ab-1/ GM-Tg-rg-IP2621-Ab-2;
GM-Tg-mg-IP2621-Ab-1/ GM-Tg-mg-IP2621-Ab-2; GM-Tg-cynog-IP2621-Ab-1/ GM-Tg-cynog-IP2621-Ab-2;
GM-Tg-felg-IP2621-Ab-1/ GM-Tg-felg-IP2621-Ab-2; GM-Tg-cang-IP2621-Ab-1/ GM-Tg-cang-IP2621-Ab-2;
GM-Tg-bovg-IP2621-Ab-1/ GM-Tg-bovg-IP2621-Ab-2; GM-Tg-equg-IP2621-Ab-1/ GM-Tg-equg-IP2621-Ab-2
Products NameAnti-NAB1 monoclonal antibody
Formatmab
Target NameNAB1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-NAB1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2621-Ag-1Recombinant multi-species NAB1 protein
    ORF Viral VectorpGMLPm002348mouse Nab1 Lentivirus plasmid
    ORF Viral VectorvGMLPm002348mouse Nab1 Lentivirus particle


    Target information

    Target IDGM-IP2621
    Target NameNAB1
    Gene ID4664,17936,64824,693274,488447,101083872,516781,100054645
    Gene Symbol and SynonymsNAB1
    Uniprot AccessionQ13506,Q62722
    Uniprot Entry NameNAB1_HUMAN,NAB1_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000138386
    Target ClassificationN/A

    The target: NAB1, gene name: NAB1, also named as . Predicted to enable transcription coregulator activity. Predicted to be involved in regulation of transcription, DNA-templated. Predicted to act upstream of or within endochondral ossification; nervous system development; and regulation of epidermis development. Predicted to be located in nucleoplasm. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.